SYLVINA 150mcg / 30mcg tablets medication leaflet

G03AA07 levonorgestrel + ethinyl estradiol • Genito urinary system and sex hormones | Hormonal contraceptives for systemic use | Progestogens and estrogens, fixed combinations

The combination of levonorgestrel and ethinylestradiol is used as an oral contraceptive to prevent pregnancy. Levonorgestrel is a progestin, and ethinylestradiol is an estrogen, both working to inhibit ovulation and alter the uterine lining.

The medication is taken orally, usually once daily at the same time, following a 21- or 28-day cycle. It is important to adhere to the administration schedule to ensure contraceptive effectiveness.

Side effects may include nausea, headaches, breast tenderness, or mood changes. In rare cases, severe reactions such as venous thromboembolism may occur.

This combination is not recommended for pregnant women, breastfeeding mothers, or patients with a history of thrombosis, severe liver disease, or hypersensitivity to any of the components.

General data about SYLVINA 150mcg / 30mcg

Substance: levonorgestrel + ethinyl estradiol

Date of last drug list: 01-01-2015

Commercial code: W61271004

Concentration: 150mcg / 30mcg

Pharmaceutical form: tablets

Quantity: 273

Product type: generic

Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

Manufacturer: LABORATORIOS LEON FARMA, S.A. - SPANIA

Holder: LABORATORIOS LEON FARMA, S.A. - SPANIA

Number: 6844/2014/04

Shelf life: 2 years

Pharmaceutical forms available for levonorgestrel + ethinyl estradiol

Concentrations available for levonorgestrel + ethinyl estradiol

0.05mg/0.03mg, 0.15mg/0.03mg, 125mcg/30mcg, 150mcg/30mcg, 150mcg/30mcg/10mcg